In the ILUVIEN Phase 3 clinical trials (FAME), there was a sustained improvement in visual acuity (VA) and reduction in retinal edema for up to 3 years1,2

The ILUVIEN CONTINUOUS MICRODOSING™ Delivery System was evaluated in 2 prospective, randomized, multicenter, double-masked, parallel 3-year clinical trials (FAME A and FAME B)2,3

ILUVIEN was studied in patients whose diabetic macular edema (DME) persisted or recurred despite treatment.1,3

  • The ILUVIEN Phase 3 clinical trials assessed patients with DME who had previously been treated with laser photocoagulation
  • Patients were treated with either ILUVIEN or sham injection (2:1)
  • All patients were allowed to receive rescue laser any time after week 6 for persistent edema or recurrent DME, if necessary

Percent of patients with an increase of ≥ 15 letters in BCVA3,4

In ILUVIEN Phase 3 clinical trials, mean retinal thickness was reduced and maintained throughout the 36-month study period3,4

Mean change from baseline in central subfield retinal thickness3,4

FAMESafety Data
FAME
Safety Data

Review safety data from the
ILUVIEN Phase 3 clinical trials.

Real-worldefficacy
Real-world
efficacy

Data from the USER Study confirm the efficacy of
ILUVIEN CONTINUOUS MICRODOSING™ Delivery.4